Page 72 - 北京京煤集团总医院第十一届·2023学术年会论文集

北京京煤集团总医院 第十一届·2023 学术年会论文集

an increased risk of DPPB. While polyp number ≥ 3 (RR=6.5,95% CI 95% CI: 0.43-98.3, P > 0.05),
polyps located in left semicolon (RR=0.84, 95% CI: 0.59-1.20, P > 0.05) or the right semicolon

(RR=1.14, 95% CI: 0.80-1.62, P > 0.05), adenoma (RR=1.70,95% CI 95% CI: 0.89-3.23, P > 0.05),
non-adenoma (RR=0.44,95% CI 95% CI: 0.08-2.51, P > 0.05), serrated polyp (RR=0.71, 95% CI:
0.20-2.44, P > 0.05) and proliferative polyp (RR=0.67, 95% CI: 0.30-1.49, P > 0.05) (Fig. S16-
22)were not associated with the incidence of DPPB (see Table 2).

3.4.4. Operation-related factors
A meta-analysis of operation-related factors was performed, including resection methods such as
EMR (6 studies [3, 8, 16, 19, 20, 22] ), ESD (2 studies [8, 22] ), HSP (4 studies [16, 19, 20, 22] ), HB (4 studies [3,
16, 19, 20] ), APC (2 studies [8, 20] ), preventive wound management (2 studies [19, 22] ), and endoscopists

experience (2 studies [7, 8, 19] ). The results showed that EMR (RR=2.34, 95% CI: 1.44-3.82, P < 0.05)
(Fig.S23) was associated with an increased risk of DPPB, while HB (RR=0.28, 95% CI: 0.17-0.46,
P < 0.05) (Fig. S24) was associated with a decreased risk of DPPB. However, ESD (RR=3.62, 95%
CI: 0.76-17.32, P > 0.05), HSP (RR=1.95,95% CI 95% CI: 0.75-5.04, P > 0.05), APC (RR=3.60,95%

CI 95% CI: 0.00-52774.53, P > 0.05), preventive wound treatment (RR=0.95, 95% CI: 0.88-1.55,
P > 0.05), inexperienced endoscopists (RR=1.55, 95% CI: 0.42-5.69, P > 0.05) and experienced
endoscopists (RR=0.65,95% CI 95% CI: 0.18-2.38, P > 0.05) (Fig. S25-30) were not associated

with the occurrence of DPPB (see Table 2).
Table 2 Single-factor logistic regression data included in the literature meta-analysis.
Study Heterogeneity
Risk Factors RR 95% CI P
Number I² (%) P

Patient related factors
Male sex 15 7.2 0.372 1.56(1.34-1.81) 0.001

Smoking 3 82.4 0.003 1.36(0.50-3.66) 0.545
Drinking 2 0.0 0.455 0.82(0.47-1.42) 0.477
Hypertension 11 22.8 0.226 1.27(1.09-1.47) 0.002
Diabetes 11 57.7 0.009 1.00(0.71-1.39) 0.983
Cardiovascular disease 9 0.0 0.549 1.56(1.23-1.97) 0.001

Cerebrovascular disease 4 0.0 0.788 1.19(0.83-1.70) 0.336
Antithrombotic drugs 7 77.0 0.000 1.96(1.24-3.09） 0.004

Aspirin 3 46.2 0.156 1.50(1.06-2.11） 0.021

Clopidogrel 2 0.0 0.363 1.89(1.03-3.45） 0.038
Warfarin 2 81.7 0.020 2.70(0.57-12.68） 0.208

Polyp-related factors
polyp number＞3 2 0.0 0.852 1.44(1.12-1.85) 0.005

polyp number ≥3 2 98.3 0.000 6.5(0.43-98.3) 0.176
Polyp size≥10 mm 3 2.3 0.359 3.57(2.58-4.95) 0.001

- 68 -